Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Andrew S. Ittleman, with Fuerst Ittleman David & Joseph. Courtesy photo. Andrew S. Ittleman. Courtesy photo.

A first-of-its-kind screening device for identifying COVID-19 biomarkers has secured emergency approval from the U.S. Food and Drug Administration, with the help of Miami’s Fuerst Ittleman founding partner Andrew S. Ittleman.

It took a year of “elbow grease, communication and patience” to get to this point, according to Ittleman, who said he’s learned the importance of building rapport and respect with the FDA, as it navigated a public health emergency.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 1 article* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

Click here to access the Public Notices and the Courts sections of the The Daily Business Review in PDF format.
Already have an account?

Raychel Lean

Raychel Lean is ALM's Florida bureau chief, overseeing the Daily Business Review. Email her at [email protected] or follow her on Twitter via @raychellean.

More from this author

Florida Affirmative Defenses and Procedural ObjectionsBook

Guides practitioners on the use, pleading, and application of defenses procedural objections in FL civil cases, surveying common and useful defensive motions and proce...

Get More Information

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.